<DOC>
	<DOCNO>NCT02799069</DOCNO>
	<brief_summary>The aim study evaluate non-inferiority BF-200 ALA ( Ameluz ) treatment actinic keratosis ( AK ) photodynamic therapy ( PDT ) compare Metvix .</brief_summary>
	<brief_title>Evaluation Safety Efficacy BF-200 ALA Treatment Actinic Keratosis With Photodynamic Therapy</brief_title>
	<detailed_description>This randomize , observer-blind , multinational , comparator placebo-controlled parallel group , ( 3:3:1 ratio ) study compare efficacy safety BF-200 ALA comparator MetvixÂ® ( methyl- [ 5-amino-4-oxopentanoate ] ) placebo , treatment AK PDT .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<mesh_term>Methyl 5-aminolevulinate</mesh_term>
	<criteria>Main Written inform consent . Men woman 18 85 year age . 48 AK lesion 0.5 1.5 cm diameter mild moderate intensity ( Olsen grade 1 2 ) face and/or bald scalp . Lesions eye , nostril , ear mouth consider treatment plan study . Target AK lesion discrete quantifiable ; adjacent AK lesion show minimum distance 1.0 cm one another . Confirmation AK biopsy take screening . Free significant physical abnormality ( e.g. , tattoo , dermatosis ) potential treatment region could cause difficulty examination final evaluation . Willingness stop use moisturizers topical treatment within treatment region . Good general health condition . Healthy subject subject clinically stable medical condition include , limited following disease ( control hypertension , diabetes mellitus type II , hypercholesterolemia , osteoarthritis ) permit include study medication take treatment disease match exclusion criterion specify prohibit concomitant medication . No extensive sunbathing solarium use trial . Negative pregnancy test screening . Main exclusion criterion : Known hypersensitivity BF200 ALA , MAL ( methylaminolevulinic acid ) and/or ingredient formulation Clinically significant medical condition ( tumor disease etc . ) make implementation protocol interpretation study result difficult Presence photodermatoses Presence tumor treatment area within last 4 week Start treatment phototoxic photoallergic drug within 8 week prior screen Current treatment immunosuppression therapy Hypersensitivity porphyrins Presence porphyria Presence inherit acquire coagulation defect Any topical treatment within treatment area within 12 week PDT1 ( first PDT Treatment ) Topical treatment ALA MAL outside treatment area participation study None specify systemic treatment within designated period PDT1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>